• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688606.SS
Share

Hangzhou Alltest Biotech Co., Ltd. Stocks

CN¥ 46.58Last Updated 21.09.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 543.73M

CN¥ 46.58
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hangzhou Alltest Biotech Co., Ltd. operates internationally, specializing in the entire process of in vitro diagnostic reagents, from their initial research and development to manufacturing and market distribution. The company supplies a wide array of rapid diagnostic solutions, encompassing crucial health sectors like women's health, infectious disease detection, drug screening, cancer diagnostics, and cardiovascular conditions, among other distinct product series. This enterprise is headquartered in Hangzhou, China.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.09.2026 01:05

The Nasdaq set a new record for the first time since June, while the S&P 500 had its best day since August

22.09.2026 00:41

The ECB has launched the first digital euro settlements in the interbank market

21.09.2026 23:48

Meta shares are having their best month in 13 years, with the price at its highest level since October. Is it too late to buy?

21.09.2026 23:31

A $30 Trillion Market and the Risk of an Apocalypse: How Much Could Anthropic Be Worth? — An FT Analysis

21.09.2026 23:15

Amazon has blocked Meta's AI agent on its marketplace. What's the issue?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026